Cargando…
LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy
BACKGROUND: The leucine rich repeat containing 3B (LRRC3B) gene is a tumor suppressor gene involved in the anti-tumor immune microenvironment. Expression of LRRC3B and DNA methylation at the LRRC3B promoter region may serve as a useful marker to predict response to anti-PD-1 therapy. However, no stu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928207/ https://www.ncbi.nlm.nih.gov/pubmed/36798137 http://dx.doi.org/10.3389/fimmu.2023.959868 |
_version_ | 1784888604506456064 |
---|---|
author | Luo, Linfeng Fu, Sha Du, Wei He, Li-na Zhang, Xuanye Wang, Yixing Zhou, Yixin Hong, Shaodong |
author_facet | Luo, Linfeng Fu, Sha Du, Wei He, Li-na Zhang, Xuanye Wang, Yixing Zhou, Yixin Hong, Shaodong |
author_sort | Luo, Linfeng |
collection | PubMed |
description | BACKGROUND: The leucine rich repeat containing 3B (LRRC3B) gene is a tumor suppressor gene involved in the anti-tumor immune microenvironment. Expression of LRRC3B and DNA methylation at the LRRC3B promoter region may serve as a useful marker to predict response to anti-PD-1 therapy. However, no studies have yet systematically explored the protective role of LRRC3B methylation in tumor progression and immunity. METHODS: Expression of LRRC3B of 33 cancer types in The Cancer Genome Atlas (TCGA) was downloaded from UCSC Xena (http://xena.ucsc.edu/). And, we evaluated the differential expression of LRRC3B according to tumor stage, overall survival, and characteristics of the tumor microenvironment. The immunotherapeutic cohorts included IMvigor21, GSE119144, and GSE72308 which were obtained from the Gene Expression Omnibus database. We conducted pearson correlation analysis of LRRC3B and tumor microenvironment (TME) in pan-cancer. Also, six immune cell types (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells) and tumor purity were analyzed using the Tumor IMmune Estimation Resource (TIMER1.0) (Tumor IMmune Estimation Resource (TIMER2.0). And, a “silencing score” model base on LRRC3B promoter methylation to predict overall survival (OS) by multivariate Cox regression analysis was constructed. Finally, the model was applied to predict anti-PD-1 therapy in non-small cell lung cancer (NSCLC) and breast cancer (BRCA). RESULTS: LRRC3B expression associated with less tumor invasion, less severe tumor stage, and decreased metastasis. The inactivation of LRRC3B promoted the enrichment of immuneosuppressive cells, including myeloid-derived suppressor cells (MDSCs), cancer-associated fibroblasts (CAFs), M2 subtype of tumor-associated macrophages (M2-TAMs), M1 subtype of tumor-associated macrophages (M1-TAMs), and regulatory T (Treg) cells. A high silencing score was significantly associated with immune inhibition, low expression of LRRC3B, poor patient survival, and activation of cancer-related pathways. CONCLUSION: Our comprehensive analysis demonstrated the potential role of LRRC3B in the anti-tumor microenvironment, clinicopathological features of cancer, and disease prognosis. It suggested that LRRC3B methylation could be used as a powerful biomarker to predict immunotherapy responses in NSCLC and BRCA. |
format | Online Article Text |
id | pubmed-9928207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99282072023-02-15 LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy Luo, Linfeng Fu, Sha Du, Wei He, Li-na Zhang, Xuanye Wang, Yixing Zhou, Yixin Hong, Shaodong Front Immunol Immunology BACKGROUND: The leucine rich repeat containing 3B (LRRC3B) gene is a tumor suppressor gene involved in the anti-tumor immune microenvironment. Expression of LRRC3B and DNA methylation at the LRRC3B promoter region may serve as a useful marker to predict response to anti-PD-1 therapy. However, no studies have yet systematically explored the protective role of LRRC3B methylation in tumor progression and immunity. METHODS: Expression of LRRC3B of 33 cancer types in The Cancer Genome Atlas (TCGA) was downloaded from UCSC Xena (http://xena.ucsc.edu/). And, we evaluated the differential expression of LRRC3B according to tumor stage, overall survival, and characteristics of the tumor microenvironment. The immunotherapeutic cohorts included IMvigor21, GSE119144, and GSE72308 which were obtained from the Gene Expression Omnibus database. We conducted pearson correlation analysis of LRRC3B and tumor microenvironment (TME) in pan-cancer. Also, six immune cell types (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells) and tumor purity were analyzed using the Tumor IMmune Estimation Resource (TIMER1.0) (Tumor IMmune Estimation Resource (TIMER2.0). And, a “silencing score” model base on LRRC3B promoter methylation to predict overall survival (OS) by multivariate Cox regression analysis was constructed. Finally, the model was applied to predict anti-PD-1 therapy in non-small cell lung cancer (NSCLC) and breast cancer (BRCA). RESULTS: LRRC3B expression associated with less tumor invasion, less severe tumor stage, and decreased metastasis. The inactivation of LRRC3B promoted the enrichment of immuneosuppressive cells, including myeloid-derived suppressor cells (MDSCs), cancer-associated fibroblasts (CAFs), M2 subtype of tumor-associated macrophages (M2-TAMs), M1 subtype of tumor-associated macrophages (M1-TAMs), and regulatory T (Treg) cells. A high silencing score was significantly associated with immune inhibition, low expression of LRRC3B, poor patient survival, and activation of cancer-related pathways. CONCLUSION: Our comprehensive analysis demonstrated the potential role of LRRC3B in the anti-tumor microenvironment, clinicopathological features of cancer, and disease prognosis. It suggested that LRRC3B methylation could be used as a powerful biomarker to predict immunotherapy responses in NSCLC and BRCA. Frontiers Media S.A. 2023-01-24 /pmc/articles/PMC9928207/ /pubmed/36798137 http://dx.doi.org/10.3389/fimmu.2023.959868 Text en Copyright © 2023 Luo, Fu, Du, He, Zhang, Wang, Zhou and Hong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Luo, Linfeng Fu, Sha Du, Wei He, Li-na Zhang, Xuanye Wang, Yixing Zhou, Yixin Hong, Shaodong LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy |
title | LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy |
title_full | LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy |
title_fullStr | LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy |
title_full_unstemmed | LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy |
title_short | LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy |
title_sort | lrrc3b and its promoter hypomethylation status predicts response to anti-pd-1 based immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928207/ https://www.ncbi.nlm.nih.gov/pubmed/36798137 http://dx.doi.org/10.3389/fimmu.2023.959868 |
work_keys_str_mv | AT luolinfeng lrrc3banditspromoterhypomethylationstatuspredictsresponsetoantipd1basedimmunotherapy AT fusha lrrc3banditspromoterhypomethylationstatuspredictsresponsetoantipd1basedimmunotherapy AT duwei lrrc3banditspromoterhypomethylationstatuspredictsresponsetoantipd1basedimmunotherapy AT helina lrrc3banditspromoterhypomethylationstatuspredictsresponsetoantipd1basedimmunotherapy AT zhangxuanye lrrc3banditspromoterhypomethylationstatuspredictsresponsetoantipd1basedimmunotherapy AT wangyixing lrrc3banditspromoterhypomethylationstatuspredictsresponsetoantipd1basedimmunotherapy AT zhouyixin lrrc3banditspromoterhypomethylationstatuspredictsresponsetoantipd1basedimmunotherapy AT hongshaodong lrrc3banditspromoterhypomethylationstatuspredictsresponsetoantipd1basedimmunotherapy |